Thalassaemia

The Lancet

Volumn 391, Issue 10116, 2018, Pages 155-167

  Taher, Ali T ^a   Weatherall, David J ^b   Cappellini, Maria Domenica ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; HEMOGLOBIN A; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; REACTIVE OXYGEN METABOLITE;

ALPHA THALASSEMIA; BETA GLOBIN GENE; BETA THALASSEMIA; CELL DEATH; CELL PROLIFERATION; CHELATION THERAPY; DISEASE BURDEN; DISEASE CLASSIFICATION; DISEASE SEVERITY; DNA DETERMINATION; ERYTHROCYTE TRANSFUSION; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GENE CLUSTER; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE PRODUCT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOSITY; HUMAN; HYPERCOAGULABILITY; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; MORBIDITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCREENING; SPLENECTOMY; SURVIVAL; THALASSEMIA; THALASSEMIA INTERMEDIA;

HUMANS; THALASSEMIA;

EID: 85026532860     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31822-6     Document Type: Review

References (139)

1. Cooley, TB, Lee, P, A series of cases of splenomegaly in children and peculiar changes in bones; report of cases. Am J Dis Child 34 (1927), 347–363.
2. Olivieri, NF, The beta-thalassemias. N Engl J Med 341 (1999), 99–109.
3. Rund, D, Rachmilewitz, E, Beta-thalassemia. N Engl J Med 353 (2005), 1135–1146.
4. Piel, FB, Weatherall, DJ, The α-thalassemias. N Engl J Med 371 (2014), 1908–1916.
5. Sankaran, VG, Nathan, DG, Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am 24 (2010), 1005–1020.
6. Sankaran, VG, Weiss, MJ, Anemia: progress in molecular mechanisms and therapies. Nat Med 21 (2015), 221–230.
7. Weatherall, DJ, Williams, TN, Allen, SJ, O'Donnell, A, The population genetics and dynamics of the thalassemias. Hematol Oncol Clin North Am 24 (2010), 1021–1031.
8. Weatherall, DJ, The inherited diseases of hemoglobin are an emerging global health burden. Blood 115 (2010), 4331–4336.
9. Christianson, A, Howson, CP, Modell, B, March of dimes global report on birth defects. The hidden toll of dying and disabled children. White Plains, 2006, March of Dimes Birth Defects Foundation, New York.
10. Modell, B, Darlison, M, Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86 (2008), 480–487.
11. Weatherall, DJ, Clegg, JB, The thalassaemia syndromes, 4th edn., 2001, Blackwell Science, Oxford.
12. Olivieri, NF, Pakbaz, Z, Vichinsky, E, Hb E/beta-thalassaemia: a common & clinically diverse disorder. Indian J Med Res 134 (2011), 522–531.
13. Cohen, AR, Galanello, R, Pennell, DJ, Cunningham, MJ, Vichinsky, E, Thalassemia. Hematology Am Soc Hematol Educ Program, 2004, 14–34.
14. Vichinsky, E, Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. Ann N Y Acad Sci 1202 (2010), 180–187.
15. Lorey, F, Cunningham, G, Vichinsky, EP, et al. Universal newborn screening for Hb H disease in California. Genet Test 5 (2001), 93–100.
16. Lorey, F, Asian immigration and public health in California: thalassemia in newborns in California. J Pediatr Hematol Oncol 22 (2000), 564–566.
17. Harteveld, CL, Higgs, DR, Alpha-thalassaemia. Orphanet J Rare Dis, 5, 2010, 13.
18. Michlitsch, J, Azimi, M, Hoppe, C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 52 (2009), 486–490.
19. Bunn, HF, Nathan, DG, Thalassemia. Bunn, HF, Aster, JC, (eds.) Pathophysiology of blood disorders, 2011, McGraw-Hill, New York, 93–104.
20. Higgs, DR, Engel, JD, Stamatoyannopoulos, G, Thalassaemia. Lancet 379 (2012), 373–383.
21. Steinberg, MH, Forget, BG, Higgs, DR, Weatherall, DJ, Disorders of hemoglobin: genetics, pathophysiology, and clinical management, 2nd edn., 2009, Cambridge University Press, New York.
22. Danjou, F, Anni, F, Galanello, R, Beta-thalassemia: from genotype to phenotype. Haematologica 96 (2011), 1573–1575.
23. Taher, A, Vichinsky, E, Musallam, K, Cappellini, MD, Viprakasit, V, Guidelines for the management of non transfusion dependent thalassaemia (NTDT), 2013, Thalassaemia International Federation, Nicosia, Cyprus.
24. Musallam, KM, Rivella, S, Vichinsky, E, Rachmilewitz, EA, Non-transfusion-dependent thalassemias. Haematologica 98 (2013), 833–844.
25. Musallam, KM, Taher, AT, Rachmilewitz, EA, β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med, 2, 2012, a013482.
26. Sankaran, VG, Orkin, SH, The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med, 3, 2013, a011643.
27. Weatherall, D, 2003 William Allan award address. The thalassemias: the role of molecular genetics in an evolving global health problem. Am J Hum Genet 74 (2004), 385–392.
28. Galanello, R, Origa, R, Beta-thalassemia. Orphanet J Rare Dis, 5, 2010, 11.
29. Sripichai, O, Makarasara, W, Munkongdee, T, et al. A scoring system for the classification of beta-thalassemia/Hb E disease severity. Am J Hematol 83 (2008), 482–484.
30. Fucharoen, S, Weatherall, DJ, The hemoglobin E thalassemias. Cold Spring Harb Perspect Med, 2, 2012, a011734.
31. Olivieri, NF, Treatment strategies for hemoglobin E beta-thalassemia. Blood Rev 26:suppl 1 (2012), S28–S30.
32. Viprakasit, V, Tyan, P, Rodmai, S, Taher, AT, Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet J Rare Dis, 9, 2014, 131.
33. Cappellini, MD, Cohen, A, Porter, J, Taher, A, Viprakasit, V, Guidelines for the management of transfusion dependent thalassaemia (TDT), 3rd edn., 2014, Thalassaemia International Federation, Nicosia, Cyprus.
34. Taher, AT, Musallam, KM, Cappellini, MD, Weatherall, DJ, Optimal management of β thalassaemia intermedia. Br J Haematol 152 (2011), 512–523.
35. Taher, A, Isma'eel, H, Cappellini, MD, Thalassemia intermedia: revisited. Blood Cells Mol Dis 37 (2006), 12–20.
36. Musallam, KM, Taher, AT, Duca, L, Cesaretti, C, Halawi, R, Cappellini, MD, Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia. Blood Cells Mol Dis 47 (2011), 232–234.
37. Rivella, S, The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev 26:suppl 1 (2012), S12–S15.
38. Rivella, S, Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 16 (2009), 187–194.
39. Taher, AT, Musallam, KM, Saliba, AN, Garziadei, G, Cappellini, MD, Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. Blood Cells Mol Dis 55 (2015), 108–109.
40. Haidar, R, Mhaidli, H, Taher, AT, Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J 19 (2010), 871–878.
41. Cappellini, MD, Poggiali, E, Taher, AT, Musallam, KM, Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol 5 (2012), 505–511 quiz 12.
42. Camaschella, C, Nai, A, Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol 172 (2016), 512–523.
43. Rivella, S, β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica 100 (2015), 418–430.
44. Musallam, KM, Cappellini, MD, Wood, JC, Taher, AT, Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev 26:suppl 1 (2012), S16–S19.
45. Rund, D, Thalassemia 2016: modern medicine battles an ancient disease. Am J Hematol 91 (2016), 15–21.
46. Taher, AT, Musallam, KM, El-Beshlawy, A, et al. Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol 150 (2010), 486–489.
47. Musallam, KM, Khoury, B, Abi-Habib, R, et al. Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol 87 (2011), 73–79.
48. Haines, D, Martin, M, Carson, S, et al. Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 160 (2013), 680–687.
49. Cazzola, M, Finch, CA, Evaluation of erythroid marrow function in anemic patients. Haematologica 72 (1987), 195–200.
50. Cazzola, M, Pootrakul, P, Huebers, HA, Eng, M, Eschbach, J, Finch, CA, Erythroid marrow function in anemic patients. Blood 69 (1987), 296–301.
51. Cazzola, M, De Stefano, P, Ponchio, L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 89 (1995), 473–478.
52. Borgna-Pignatti, C, Rugolotto, S, De Stefano, P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89 (2004), 1187–1193.
53. Modell, B, Khan, M, Darlison, M, Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355 (2000), 2051–2052.
54. Cao, A, Quality of life and survival of patients with beta-thalassemia major. Haematologica 89 (2004), 1157–1159.
55. O'Donnell, A, Premawardhena, A, Arambepola, M, et al. Age-related changes in adaptation to severe anemia in childhood in developing countries. Proc Natl Acad Sci U S A 104 (2007), 9440–9444.
56. Allen, A, Fisher, C, Premawardhena, A, et al. Adaptation to anemia in hemoglobin E-β thalassemia. Blood 116 (2010), 5368–5370.
57. Olivieri, NF, Muraca, GM, O'Donnell, A, Premawardhena, A, Fisher, C, Weatherall, DJ, Studies in haemoglobin E beta-thalassaemia. Br J Haematol 141 (2008), 388–397.
58. Vichinsky, E, Advances in the treatment of alpha-thalassemia. Blood Rev 26:suppl 1 (2012), S31–S34.
59. Taher, A, Isma'eel, H, Mehio, G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 96 (2006), 488–491.
60. Taher, AT, Musallam, KM, Karimi, M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 115 (2010), 1886–1892.
61. Musallam, KM, Taher, AT, Karimi, M, Rachmilewitz, EA, Cerebral infarction in β-thalassemia intermedia: breaking the silence. Thromb Res 130 (2012), 695–702.
62. Porter, JB, Practical management of iron overload. Br J Haematol 115 (2001), 239–252.
63. Brittenham, GM, Iron-chelating therapy for transfusional iron overload. N Engl J Med 364 (2011), 146–156.
64. Berdoukas, V, Nord, A, Carson, S, et al. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. Am J Hematol 88 (2013), E283–E285.
65. Borgna-Pignatti, C, Meloni, A, Guerrini, G, et al. Myocardial iron overload in thalassaemia major. How early to check?. Br J Haematol 164 (2014), 579–585.
66. Wood, JC, Origa, R, Agus, A, Matta, G, Coates, TD, Galanello, R, Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica 93 (2008), 917–920.
67. Yang, G, Liu, R, Peng, P, et al. How early can myocardial iron overload occur in beta thalassemia major?. PLoS One, 9, 2014, e85379.
68. Voskaridou, E, Ladis, V, Kattamis, A, et al. A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol 91 (2012), 1451–1458.
69. Musallam, KM, Cappellini, MD, Daar, S, et al. Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study. Haematologica 99 (2014), e218–e221.
70. Lal, A, Goldrich, ML, Haines, DA, Azimi, M, Singer, ST, Vichinsky, EP, Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 364 (2011), 710–718.
71. Origa, R, Barella, S, Argiolas, GM, Bina, P, Agus, A, Galanello, R, No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica 93 (2008), 1095–1096.
72. Taher, AT, Musallam, KM, Wood, JC, Cappellini, MD, Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol 85 (2010), 288–290.
73. Roghi, A, Cappellini, MD, Wood, JC, et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol 89 (2010), 585–589.
74. Mavrogeni, S, Gotsis, E, Ladis, V, et al. Magnetic resonance evaluation of liver and myocardial iron deposition in thalassemia intermedia and b-thalassemia major. Int J Cardiovasc Imaging 24 (2008), 849–854.
75. Musallam, KM, Motta, I, Salvatori, M, et al. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. Blood Cells Mol Dis 49 (2012), 136–139.
76. Maakaron, JE, Cappellini, MD, Graziadei, G, Ayache, JB, Taher, AT, Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. Ann Hepatol 12 (2013), 142–146.
77. Musallam, KM, Cappellini, MD, Wood, JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 96 (2011), 1605–1612.
78. Musallam, KM, Cappellini, MD, Taher, AT, Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia. Blood Cells Mol Dis 51 (2013), 35–38.
79. Ziyadeh, FN, Musallam, KM, Mallat, NS, et al. Glomerular hyperfiltration and Pproteinuria in transfusion-independent patients with β-thalassemia intermedia. Nephron Clin Pract 121 (2012), c136–c143.
80. Musallam, KM, Beydoun, A, Hourani, R, et al. Brain magnetic resonance angiography in splenectomized adults with β-thalassemia intermedia. Eur J Haematol 87 (2011), 539–546.
81. Musallam, KM, Nasreddine, W, Beydoun, A, et al. Brain positron emission tomography in splenectomized adults with β-thalassemia intermedia: uncovering yet another covert abnormality. Ann Hematol 91 (2012), 235–241.
82. Musallam, KM, Angastiniotis, M, Eleftheriou, A, Porter, JB, Cross-talk between available guidelines for the management of patients with beta-thalassemia major. Acta Haematol 130 (2013), 64–73.
83. Belhoul, KM, Bakir, ML, Saned, MS, Kadhim, AM, Musallam, KM, Taher, AT, Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol 91 (2012), 1107–1114.
84. Olivieri, NF, Nathan, DG, MacMillan, JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331 (1994), 574–578.
85. Aessopos, A, Fragodimitri, C, Karabatsos, F, et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 92 (2007), 131–132.
86. Worwood, M, Cragg, SJ, Jacobs, A, McLaren, C, Ricketts, C, Economidou, J, Binding of serum ferritin to concanavalin A: patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol 46 (1980), 409–416.
87. Taher, A, El Rassi, F, Isma'eel, H, Koussa, S, Inati, A, Cappellini, MD, Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 93 (2008), 1584–1586.
88. Angelucci, E, Brittenham, GM, McLaren, CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343 (2000), 327–331.
89. Siegel, CA, Silas, AM, Suriawinata, AA, van Leeuwen, DJ, Liver biopsy 2005: when and how?. Cleve Clin J Med 72 (2005), 199–201 206, 208 passim.
90. Fischer, R, Piga, A, Harmatz, P, Nielsen, P, Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci 1054 (2005), 350–357.
91. St Pierre, TG, Clark, PR, Chua-anusorn, W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 (2005), 855–861.
92. Hankins, JS, McCarville, MB, Loeffler, RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 113 (2009), 4853–4855.
93. Kirk, P, He, T, Anderson, LJ, et al. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging 32 (2010), 315–319.
94. St Pierre, TG, El-Beshlawy, A, Elalfy, M, et al. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. Magn Reson Med 71 (2014), 2215–2223.
95. Wood, JC, Enriquez, C, Ghugre, N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106 (2005), 1460–1465.
96. Wood, JC, Zhang, P, Rienhoff, H, Abi-Saab, W, Neufeld, E, R2 and R2* are equally effective in evaluating chronic response to iron chelation. Am J Hematol 89 (2014), 505–508.
97. Carpenter, JP, He, T, Kirk, P, et al. On T2* magnetic resonance and cardiac iron. Circulation 123 (2011), 1519–1528.
98. Wood, JC, Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program 2011 (2011), 443–450.
99. Noetzli, LJ, Panigrahy, A, Mittelman, SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 87 (2012), 167–171.
100. Noetzli, LJ, Mittelman, SD, Watanabe, RM, Coates, TD, Wood, JC, Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 87 (2012), 155–160.
101. Olivieri, NF, Brittenham, GM, Iron-chelating therapy and the treatment of thalassemia. Blood 89 (1997), 739–761.
102. Angelucci, E, Muretto, P, Nicolucci, A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100 (2002), 17–21.
103. Telfer, PT, Prestcott, E, Holden, S, Walker, M, Hoffbrand, AV, Wonke, B, Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 110 (2000), 971–977.
104. Anderson, LJ, Holden, S, Davis, B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22 (2001), 2171–2179.
105. Kirk, P, Roughton, M, Porter, JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120 (2009), 1961–1968.
106. Carpenter, JP, Roughton, M, Pennell, DJ, Myocardial Iron in Thalassemia Investigators. International survey of T2* cardiovascular magnetic resonance in β-thalassemia major. Haematologica 98 (2013), 1368–1374.
107. Aydinok, Y, Porter, JB, Piga, A, et al. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol 95 (2015), 244–253.
108. Pennell, DJ, Porter, JB, Piga, A, et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood 123 (2014), 1447–1454.
109. Davis, BA, Porter, JB, Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 95 (2000), 1229–1236.
110. Pennell, DJ, Berdoukas, V, Karagiorga, M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107 (2006), 3738–3744.
111. Tanner, MA, Galanello, R, Dessi, C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115 (2007), 1876–1884.
112. Tanner, MA, Galanello, R, Dessi, C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson, 10, 2008, 12.
113. Farmaki, K, Tzoumari, I, Pappa, C, Chouliaras, G, Berdoukas, V, Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148 (2010), 466–475.
114. Farmaki, K, Tzoumari, I, Pappa, C, Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis 47 (2011), 33–40.
115. Pennell, DJ, Porter, JB, Cappellini, MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica 97 (2012), 842–848.
116. Cappellini, MD, Bejaoui, M, Agaoglu, L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 118 (2011), 884–893.
117. Pathare, A, Taher, A, Daar, S, Deferasirox (exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol 89 (2010), 405–409.
118. Taher, A, Cappellini, MD, Vichinsky, E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 147 (2009), 752–759.
119. Deugnier, Y, Turlin, B, Ropert, M, et al. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 141 (2011), 1202–1211.
120. Casale, M, Citarella, S, Filosa, A, et al. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major. Am J Hematol 89 (2014), 1102–1106.
121. Taher, AT, Porter, JB, Viprakasit, V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol 92 (2013), 1485–1493.
122. Fisher, SA, Brunskill, SJ, Doree, C, Chowdhury, O, Gooding, S, Roberts, DJ, Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev, 8, 2013 CD004839.
123. Mamtani, M, Kulkarni, H, Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol 141 (2008), 882–890.
124. Porter, JB, Wood, J, Olivieri, N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson, 15, 2013, 38.
125. Gabutti, V, Piga, A, Results of long-term iron-chelating therapy. Acta Haematol 95 (1996), 26–36.
126. Delea, TE, Edelsberg, J, Sofrygin, O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 47 (2007), 1919–1929.
127. Premawardhena, A, Fisher, CA, Olivieri, NF, et al. Haemoglobin E beta thalassaemia in Sri Lanka. Lancet 366 (2005), 1467–1470.
128. Taher, AT, Musallam, KM, Karimi, M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 8 (2010), 2152–2158.
129. Angelucci, E, Matthes-Martin, S, Baronciani, D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 99 (2014), 811–820.
130. Angelucci, E, Hematopoietic stem cell transplantation in thalassemia. Hematology Am Soc Hematol Educ Program 2010 (2010), 456–462.
131. Cavazzana-Calvo, M, Payen, E, Negre, O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467 (2010), 318–322.
132. Musallam, KM, Taher, AT, Cappellini, MD, Sankaran, VG, Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood 121 (2013), 2199–2212 quiz 2372.
133. Dussiot, M, Maciel, TT, Fricot, A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med 20 (2014), 398–407.
134. Suragani, RN, Cadena, SM, Cawley, SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 20 (2014), 408–414.
135. Gardenghi, S, Ramos, P, Marongiu, MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest 120 (2010), 4466–4477.
136. Preza, GC, Ruchala, P, Pinon, R, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest 121 (2011), 4880–4888.
137. Nai, A, Pagani, A, Mandelli, G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. Blood 119 (2012), 5021–5029.
138. Guo, S, Casu, C, Gardenghi, S, Booten, S, Aghajan, M, Peralta, R, et al. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest 123 (2013), 1531–1541.
139. Schmidt, PJ, Toudjarska, I, Sendamarai, AK, et al. An RNAi therapeutic targeting TMPRSS6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Blood 121 (2013), 1200–1208.